12 January 2023 - - US-based Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, has engaged Destum Partners, Inc. to serve as the exclusive advisor for the company's partnering and licensing efforts in strategic global markets, the company said.

This initial engagement will encompass the company's two over-the-counter product candidates, Epoladerm, indicated for osteoarthritis pain, and AnQlar, an intranasal mucosal viral barrier.

Additionally, Destum Partners will work with Virpax on identifying a partner in the animal health market for its Rx product candidate, Probudur, a long-acting local anesthetic indicated for postoperative pain management.

Destum Partners, Inc. is an advisory and consultancy firm specializing in the biopharmaceutical and life sciences industries.

For more than 15 years, Destum Partners has worked with clients ranging from large, multinational Fortune 500 companies through mid-sized/early-stage companies, globally completing transactions and providing customized market research and valuations.

Destum Partners is therapeutically agnostic and has completed over USD 3.75bn in deal value.

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery.

Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms.

Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

Virpax is also using its intranasal Molecular Envelope Technology to develop two other product candidates.

PES200 is a product candidate being developed to manage post-traumatic stress disorder and NobrXiol is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol for the management of rare pediatric epilepsy.

Virpax recently acquired global rights to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis.